By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Global Blood Therapeutics 

400 E. Jamie Court
Suite 101
South San Francisco  California  94080  U.S.A.
Phone: 650-741-7700 Fax: n/a


SEARCH JOBS

Global Blood Therapeutics is developing novel, orally-available therapeutics designed to change the treatment paradigm for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options.

The current standard of care treats the symptoms during acute episodes; however, the underlying pathology of the disease causes progressive damage to the body. Global Blood Therapeutics is focused on the critical need for therapeutics that address the causes of blood diseases, not just the symptoms.

Global Blood Therapeutics’ extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics.

The Company has built a pipeline of preclinical programs focused on several blood diseases. Its lead program is in sickle cell disease, a global health challenge with very limited treatment options and none that address the underlying cause of the disease. The Company’s pipeline also includes a novel therapeutic for hereditary angioedema.

Global Blood Therapeutics is a private Company led by an experienced management team with a track record of four successful drug approvals and more than 30 investigational new drug applications. Backed by Third Rock Ventures, the Company was founded in 2012 with a $40.7 million Series A financing.


Key Statistics


Email: info@globalbloodtx.com
Ownership: Public

Web Site: Global Blood Therapeutics
Employees: n/a
Symbol: GBT
 



Industry
Biotechnology






Company News
Global Blood Therapeutics (GBT) Announces New Details On Its Novel Patient Reported Outcomes (PRO) Tool To Be Used In Phase III HOPE Study 12/6/2016 8:05:25 AM
Global Blood Therapeutics (GBT) Announces New Long-Term Clinical Data From Ongoing Phase I/II Trial Of GBT440 In Sickle Cell Disease At American Society of Hematology 12/5/2016 8:54:40 AM
Global Blood Therapeutics (GBT) Announces GBT440 Granted Orphan Drug Designation In Europe For Treatment Of Sickle Cell Disease 12/1/2016 7:43:55 AM
Global Blood Therapeutics (GBT) Announces Upcoming Investor Webcast To Review GBT440 Data Being Presented At American Society of Hematology That Support Sickle Cell Disease Program 12/1/2016 7:40:53 AM
Global Blood Therapeutics (GBT) Announces Initiation Of Phase IIa Trial Of GBT440 In Idiopathic Pulmonary Fibrosis (IPF) 11/28/2016 7:13:28 AM
[} Reports Recent Business Progress And Provides Third Quarter 2016 Financial Results 11/10/2016 1:52:30 PM
Bay Area's Global Blood Therapeutics (GBT) and the FDA Finally Reach Agreement on Trial Design for Sickle Cell Disease Drug 10/25/2016 5:53:18 AM
Global Blood Therapeutics (GBT) Announces Appointment Of Tricia Suvari As Chief Legal Officer 10/12/2016 8:26:01 AM
Global Blood Therapeutics (GBT) Presents GBT440 Data That Continue To Support Durability, Safety And Mechanism Of Action In Sickle Cell Disease 10/7/2016 9:35:57 AM
Global Blood Therapeutics (GBT) Announces Publication Of Preclinical Results Supporting GBT440 Program For Hypoxemic Pulmonary Disorders 9/15/2016 9:00:36 AM
12345
//-->